sarah Chorley, Author at Cycle Vita

Multiple sclerosis patients in US left without essential patient support program will now receive equivalent backing from Cycle Pharmaceuticals following FDA’s approval of TASCENSO ODT^® (fingolimod)

Cycle Pharmaceuticals Ltd (Cycle) is pleased to announce its intention to commercialize TASCENSO ODT® (fingolimod) in the US multiple sclerosis (MS) market in Q1 2023.
Eligible patients will receive full MS patient support program through Cycle Vita™

Author: sarah Chorley

Multiple sclerosis patients in US left without essential patient support program will now receive equivalent backing from Cycle Pharmaceuticals following FDA’s approval of TASCENSO ODT^® (fingolimod)

Cycle Pharmaceuticals to launch TASCENSO ODT® (fingolimod) in US in Q1 2023